

Institutional Review Board (IRB) Policies & Procedures Manual



Document: irbm-002-014-dfci-bch-reliance-chart .docx

Reliance Agreement with Dana-Farber Cancer Institute (DFCI)

Boston Children’s Hospital is one of the institutions participating with the Dana-Farber Harvard Cancer Institute. As such, all Cancer-related research will be reviewed through the DFCI IRB.

Boston Children’s Hospital and DFCI share a scientific review committee for the department of hematology/oncology. The chart summarizes which IRB will review the research.

The chart indicates how to determine which (BCH or DF/HCC) scientific review committee, IRB, and DSMC are appropriate for studies conducted in the Division of Pediatric Hematology/Oncology*(abbreviations defined below).

- **DF/HCC = Dana Farber/Harvard Cancer Center**
- **BCH= Boston Children’s Hospital**
- **SRC= Scientific Review Committee (adults)**
- **PSRC=Pediatric Scientific Review Committee**
 - **PSRC is the same committee as DF/HCC PSRC, but does not include DF/HCC follow-up (from investigator standpoint, submission is via usual process)**

Type of trial	Scientific Review	IRB	Data safety and monitoring responsibility
Pediatric oncology	DF/HCC PSRC	DF/HCC IRB-G	DF/HCC
Adult and Pediatric hematology- oncology	DF/HCC SRC or PSRC	DF/HCC IRB-G	DF/HCC
Transplant protocols: cancer	DF/HCC PSRC	DF/HCC IRB-G	DF/HCC

Transplant protocols: non-cancer	PSRC or Catalyst*	BCH IRB	BCH
Genetic therapies: cancer	DF/HCC PSRC	DF/HCC IRB-G	DF/HCC
Genetic therapies: non- cancer	PSRC or Catalyst*	BCH IRB	BCH
Greater than minimal risk non- malignant hematology – conducted at BCH only	DF/HCC PSRC or Catalyst	BCH IRB	BCH
Non-malignant hematology, multi-site within the DF/HCC institutions	DF/HCC SRC or PSRC	DFCI (non-cancer center)	DF/HCC
Minimal risk non- malignant hematology	Conducted at BCH only		
Any protocol (minimal risk and therapeutic) that is for patients (including oncology patients but not exclusive to oncology patients) that is looking at a non-oncology intervention or endpoint (e.g. new treatment for fungemia; psychological outcomes after ICU hospitalization) **	Scientific review in department conducting the research	BCH IRB	BCH

Any protocol (minimal risk and therapeutic) for oncology patients exclusively that is looking at a non-oncology intervention or endpoint (e.g. new PET scan process for patients with tumors; surgical outcomes after limb sparing procedures for extremity osteo)	DF/HCC PSRC	DF/HCC IRB-G	DF/HCC
Observational studies in pediatric oncology, including biology studies (when separate from clinical trials), biobanking protocols, chart reviews, genetic studies, surveys, outcomes or health services research.	DF/HCC PSRC	DF/HCC IRB-D	NONE
Psychosocial or behavioral intervention studies involving pediatric oncology patients only	DF/HCC PSRC	DF/HCC IRB-D	DF/HCC

*If cell manipulation at DFCI GMP facility, requires agreement of reliance by DFCI IRB on BCH IRB review, contact Dr. Jerome Ritz.

**If there are questions they may be referred to Robleinsky Dominguez (BCH) and Porsha Lark (DFCI).

Document Attributes

Title	Reliance Agreement with Dana-Farber Cancer Institute		
Author	Susan Kornetsky	Dates Reviewed/ Revised	2/19/2015
Reviewed/ Revised by	Susan Kornetsky		6/5/2020

Copyright	©Boston Children’s Hospital, 2020	Last Modified	6/5/2020
Approved	Susan Kornetsky, MPH Director of Clinical Research Compliance		
	August Cervini, MBA Vice President for Research Administration		